Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,710 total articles
Helen Torley, President and CEO of Halozyme Therapeutics (NASDAQ: HALO), sold 39,000 shares of company stock across multiple transactions on April 1 and April 2, 2026, generating roughly $2.59 million. On the same dates she exercised options to acquire 40,000 shares at $12.07 each, costing $482,800. The transactions are disclosed in an SEC Form 4 f…
Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn sold 4,683 shares on April 1, 2026, for $20.97 apiece, totaling $98,202. The transaction, executed under a Rule 10b5-1 trading plan, left Horn with 80,351 shares. Meanwhile, the FDA accepted a resubmitted Biologics License Application for UX111 with a Prescription Drug User Fee Act …
Cardlytics Inc. Chief Executive Officer Amit Gupta sold 116,774 shares of common stock on April 1 and April 2, 2026, for approximately $118,425 in aggregate. The transactions occurred while the stock traded at $1.13, down 52% over six months. The company posted a slight revenue beat for fiscal 2025 fourth quarter and completed the sale of its Bridg…
Cardlytics Chief Legal & Privacy Officer Lynton Nicholas Hollmeyer reported a sale of 40,296 shares of company stock on April 1, 2026, at a weighted average price of $0.99 for proceeds of $39,893, while on the same day exercising restricted stock units that resulted in the acquisition of 85,590 shares. The company recently posted mixed fourth-quart…
Rush Street Interactive Chief Executive Officer Richard Todd Schwartz sold 90,482 shares of the company’s Class A common stock on April 1, 2026, for roughly $1.99 million under a pre-arranged 10b5-1 plan. The divestiture occurred as RSI shares traded near a 52-week peak following a 99% gain over the past 12 months. Multiple analysts have recently a…
Director Stuart N. Bernstein sold 4,071 shares of Xos, Inc. common stock on March 31, 2026, in a trade totaling $6,693. The company reported a shift to profitability and positive cash flow for 2025 despite a drop in annual revenue; the shares have also been under recent pressure and are trading near a 52-week low.
Rush Street Interactive Chief Operating Officer Mattias Stetz sold 20,000 Class A shares on April 1, 2026, generating proceeds of $441,444 at a weighted average price of $22.0722. The trade, carried out under a pre-arranged 10b5-1 plan, occurred as RSI traded close to a 52-week high of $22.80 following a nearly 99% gain over the past year. Stetz co…
Outfront Media Executive Vice President and Chief Financial Officer Matthew Siegel disposed of 50,000 shares on March 31, 2026, generating $1.29 million in proceeds. The sale, executed under a Rule 10b5-1 plan adopted in December 2025, occurred while the stock traded close to its 52-week peak. The company recently reported fourth-quarter 2025 resul…
Snowflake Inc. SVP of Engineering Vivek Raghunathan executed a sale of 3,876 shares on April 1, 2026, generating $592,252 in proceeds under a pre-arranged 10b5-1 plan. The transaction was disclosed in a Form 4 filing. The company also named Jonathan Beaulier as Chief Revenue Officer following Mike Gannon's departure, a move noted by several analyst…
DocuSign Chief Revenue Officer Paula Hansen sold 6,000 shares of DOCU on April 1, 2026 under a prearranged 10b5-1 plan, generating $281026. The trades were split across three executions at price ranges between $45.85 and $48.00. Following the sales Hansen retains direct ownership of 79,233 shares. The move comes as the stock trades near its 52-week…
DocuSign President and CEO Allan C. Thygesen sold 26,250 shares of the company's common stock on April 1, 2026, generating roughly $1.25 million in proceeds. The transactions were executed in three tranches at prices between $45.89 and $48.38 and were carried out under a Rule 10b5-1 plan. Following the sales Thygesen retains direct ownership of 152…
DocuSign Chief Legal Officer James P. Shaughnessy executed the sale of 12,000 shares on April 1, 2026, under a pre-established Rule 10b5-1 plan, generating proceeds of $562,011. The trades were split across three price bands. The sale occurs amid mixed analyst signals, price-target cuts and growing focus on AI revenue as a potential catalyst for th…
WEX Inc. COO Joel Alan Dearborn Jr. sold 3,503 shares on April 1, 2026, through an automatic Rule 10b5-1 plan for $532,488. The shares traded between $147.93 and $152.71. WEX reported stronger-than-expected fourth-quarter 2025 results and continues active buybacks, yet shares declined amid broader market concerns and analysts maintained neutral-to-…
Netflix director Reed Hastings sold $40.1 million in company shares on April 1, 2026, while exercising options and acquiring additional option rights. The moves come as Netflix implements U.S. subscription price increases and pursues an expanded NFL game package, with several analysts maintaining positive ratings and price targets.
Travere Therapeutics CEO Eric M. Dube sold 60,000 shares of company stock on April 1, 2026, in two tranches for roughly $1.8 million while exercising options to acquire 60,000 shares the same day. The transactions were conducted under a June 16, 2025 written 10b5-1 plan and follow a year in which the stock has risen 70%. Separately, the FDA pushed …
Elizabeth E. Reed, Travere Therapeutics' chief legal officer and general counsel, sold 10,000 shares of the company's common stock on April 1, 2026, for $300,000 and exercised options for an additional 10,000 shares the same day. The company is concurrently managing an extended FDA review for its Filspari supplemental New Drug Application, with a n…
SoftVest, L.P. purchased 12,893 units of Cross Timbers Royalty Trust (CRT) on March 31 and April 1, 2026, paying roughly $10.50 per unit for a total outlay of $135,376, according to a Securities and Exchange Commission Form 4 filing. The purchases raised SoftVest's direct ownership to 710,744 units as CRT shares trade near $10.75 and InvestingPro f…
Andrew Shafer, Gevo's Chief Customer, Market & Brand Officer, sold 5,550 shares on April 1, 2026, receiving $15,027 and on the same day exercised options to acquire 5,550 shares at $0.71. The transactions were carried out under a 10b5-1 trading plan adopted November 19, 2025. Following the activity Shafer holds 270,823 shares directly and 16,871.52…
Qualcomm SVP and Chief Accounting Officer Patricia Y. Grech sold 85 shares on April 2, 2026, under a pre-arranged Rule 10b5-1 plan. The trade, worth $10,667 at $125.50 per share, comes as Qualcomm shares trade near a 52-week low and following company moves to raise its dividend and authorize a large buyback program. Analysts have issued mixed ratin…
Gregory D. Patrinely, Sable Offshore Corp's executive vice president and chief financial officer, disposed of 279,081 shares on March 31, 2026, in a Form 4 filing. The sale, executed at $16.6893 per share for a total of $4,657,666, was reported as a tax-withholding action tied to restricted stock vesting. Sable Offshore is concurrently reporting op…
Steel Connect Sub LLC increased its direct holding in Spruce Power Holding Corp through two purchases totaling 12,637 shares for $50,913. The transactions were disclosed in a Form 4 filing that lists a group of reporting entities potentially part of a 13(d) group holding more than 10% of Spruce Power's common stock. Separately, Spruce Power reporte…
Dmitry Zamansky, Amwell's Chief Product & Technology Officer, sold 5,575 Class A shares on April 1, 2026, in an automatic sell-to-cover tied to restricted stock unit vesting. The transaction raised $29,547 at $5.30 per share. The firm reported a 22.1% year-over-year revenue decline in Q4 2025, a loss of $5.96 per share over the trailing twelve mont…
Nasdaq Inc. Chair and CEO Adena T. Friedman executed employee stock options for 113,611 shares and concurrently sold the same number of shares on April 1, 2026. The stock sale generated $9.71 million at an average price of $85.44. Nasdaq also updated medium-term revenue guidance and disclosed partnerships and tokenization plans.
Entrada Therapeutics Chief Financial Officer Wentworth Kory James sold 2,500 shares of common stock on April 1, 2026 for $12.95 per share, a transaction totaling $32,375. The sale, carried out under a Rule 10b5-1 plan adopted in March 2025, leaves Wentworth with direct ownership of 119010 shares. The divestiture comes as TRDA trades near its 52-wee…
Lightwave Logic director Ronald A. Bucchi sold 11,000 shares of common stock on April 1, 2026, at a weighted average price of $6.92, generating about $76,120. The disposition followed the conversion of restricted stock units that vested on March 31, 2026, and was executed to meet tax withholding obligations. The company reported a 147% year-over-ye…
